

Terumo Revises its Full-Year Financial Guidance for FY2020

TOKYO, JAPAN – November 5, 2020 – Terumo Corporation (TSE: 4543) today announced that it revised the full-year financial guidance for the year ending March 2021 (FY2020) which was announced on August 6.

1. Full-year financial guidance for FY2020 (From April 1, 2020 to March 31, 2021)

	Revenue (Million JPY)	Adjusted operating profit (Million JPY)	Operating profit (Million JPY)	Profit for the year attributable to the owners of the parent (Million JPY)	Earnings per share (JPY)
Prior guidance	600,000	103,000	85,000	65,000	86.19
Revised guidance	600,000	108,000	90,000	68,000	90.07
Change in amount	0	5,000	5,000	3,000	
Rate of change	0%	4.9%	5.9%	4.6%	
(Reference) Results for the prior fiscal year	628,897	124,998	110,611	85,211	113.96

2. Reasons for the revision

Terumo estimates that the influence of COVID-19 will be limited on General Hospital Company as well as Blood and Cell Technologies Company, and relatively large on Cardiac and Vascular Company. As a whole, the pandemic will affect revenue and profit negatively.

Contrary to Terumo's assumption on August 6, the negative financial impact of COVID-19 during the second quarter was milder, resulting in revenue and each profit* exceeding the prior forecast.

Meanwhile, Terumo anticipates the recovery of demand for healthcare during the second half to be slower than the company's assumption in August. Thus, though the company does not revise its guidance on revenue, Terumo intends to continue managing SG&A expenses according to the situation, and expects its full-year each profit* to exceed the prior guidance.

The financial impact of COVID-19 resurgence is not incorporated in the guidance above.

At this point in time, Terumo does not change its projections of cash dividends from the financial statement disclosed in May. Both the interim and full-year dividends per share will be JPY 14.00 respectively.

* Adjusted operating profit, operating profit, and profit for the year attributable to the owners of the parent

About Terumo

Terumo (TSE: 4543) is a global leader in medical technology and has been committed to "Contributing to Society through Healthcare" for nearly 100 years. Based in Tokyo and operating globally, Terumo employs more than 25,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.

Disclaimer

Among the information that Terumo discloses, the forward-looking statements including financial projections contain potential risks and uncertainty since these are made by Terumo based on limited information available at the moment of disclosure. Accordingly, it should be noted that actual results might differ from those statements due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.

###